M.D., Tufts University
American Board of Internal Medicine, Infectious Diseases
HIV molecular biology and virology, latency and persistence of HIV infection, antiretroviral therapy and clinical/translational investigation. Margolis lab web site.
My laboratory has a long history of translational HIV research: investigating basic molecular, virological, and immunological phenomenon, and leveraging insights to develop new interventions in HIV disease. While my work has involved many aspects of HIV science and medicine, for the last two decades a central focus has been the study of molecular mechanisms of HIV proviral latency and persistence despite potent antiretroviral therapy (ART). We have begun to define the role of epigenetic factors in the restriction of HIV expression, and this has led to diverse, multidisciplinary collaborations and translational clinical studies resulting in discovery and high-impact work. I am the principal investigator for CARE (Collaboratory of AIDS Researchers for Eradication), an NIH-funded research organization that seeks to develop the tools to bring an HIV cure from the bench to the clinic. I serve as principal investigator of two NIH-funded studies to combine biologics (broadly-neutralizing antibodies or antiviral T cell infusions) and small-molecule anti-latency agent (HDAC inhibitor) in FDA-approved investigations to attempt to precisely document the depletion of persistent HIV infection. Finally, I direct the UNC HIV Cure Center, created to support novel and impactful research needed to advance towards therapies to induce an HIV remission. We currently support 7 junior faculty scientists in a multidisciplinary environment ideal for training and translational research.